Xenetic Biosciences
XBIO
8 hedge funds and large institutions have $581K invested in Xenetic Biosciences in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
14% more funds holding
Funds holding: 7 → 8 (+1)
0.11% more ownership
Funds ownership: 0.75% → 0.86% (+0.11%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
21% less capital invested
Capital invested by funds: $736K → $581K (-$155K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.45M |
| 2 |
VF
Virtu Financial
New York
|
+$125K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$60.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$3.29K |
| 5 |
CA
Crewe Advisors
Salt Lake City,
Utah
|
+$429 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$128K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $484K | +$1.45M | +40,455 | New |
|
|
VF
2
Virtu Financial
New York
| $42K | +$125K | +3,506 | New |
|
3
Royal Bank of Canada
Toronto,
Ontario, Canada
| $32K | – | – | – |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $20K | +$60.4K | +1,690 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $3K | +$3.29K | +92 | +50% |
|
|
RE
6
RBC Europe
London,
United Kingdom
| $127 | – | – | – |
|
|
7
Morgan Stanley
New York
| – | -$128K | -3,582 | -99% |
|
|
PAM
8
Panagora Asset Management
Boston,
Massachusetts
| – | -$4K | -34 | Closed |
|
|
CA
9
Crewe Advisors
Salt Lake City,
Utah
| – | +$429 | +12 | New |
|
XBIO Hedge Fund Activity: Q3 2019 in Review
8 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q3 2019, worth a combined $581K — down 21% from $736K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new XBIO positions and 3 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.45M. The largest seller was Morgan Stanley, cutting an estimated $128K.
- 8 institutional investors held Xenetic Biosciences (XBIO) as of Q3 2019, up from 7 in Q2 2019.
- Funds reported $581K of Xenetic Biosciences stock for Q3 2019, down 21% quarter-over-quarter.
- 4 funds opened new Xenetic Biosciences positions in Q3 2019 and 3 closed out, a net change of +1 holder.
- The largest Xenetic Biosciences buyer in Q3 2019 was Sabby Management, an estimated $1.45M added.
- The largest Xenetic Biosciences seller in Q3 2019 was Morgan Stanley, an estimated $128K sold.
Based on aggregated 13F filings for Q3 2019.